Page 107 - 2019_02-Haematologica-web

IDH1/2 mutations in remission predict AML relapse
models, and clinical opportunities. Cancer
Discov. 2013;3(7):730-741.
16. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-
hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenas- es. Cancer Cell. 2011;19(1):17-30.
17. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic dif- ferentiation. Cancer Cell. 2010;18(6):553-567.
18. Chou WC, Peng KY, Lei WC, et al. Persistence of mutant isocitrate dehydroge- nase in patients with acute myeloid leukemia in remission. Leukemia. 2012;26(3):527-529.
19. Debarri H, Lebon D, Roumier C, et al. IDH1/2 but not DNMT3A mutations are sui targets for minimal residual disease monitor- ing in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget. 2015;6(39):42345- 42353.
20. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129 (4):424-447.
21. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neo- plasms and acute leukemia. Blood. 2016;127(20):2391-2405.
22. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191- 2194.
23. Ok CY, Patel KP, Garcia-Manero G, et al. TP53 mutation characteristics in therapy- related myelodysplastic syndromes and
acute myeloid leukemia is similar to de novo
diseases. J Hematol Oncol. 2015;8:45-52. 24. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat
Biotechnol. 2011;29(1):24-26.
25. den Dunnen JT, Dalgleish R, Maglott DR, et
al. HGVS Recommendations for the descrip- tion of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564-569.
etry immunophenotypic analysis and quan- titative RT-PCR for the detection of minimal residual disease of core binding factor acute myeloid leukemia. Am J Clin Pathol. 2016;145(6):769-777.
33. Xu J, Jorgensen JL, Wang SA. How do we use multicolor flow cytometry to detect minimal residual disease in acute myeloid leukemia? Clin Lab Med. 2017;37(4):787-
26. Chen W, Jones D, Medeiros LJ, Luthra R, Lin 802.
P. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplica- tion and point mutation type. Br J Haematol. 2005;130(5):726-728.
27. Tang Z, Medeiros LJ, Yin CC, et al. Sex chro- mosome loss after allogeneic hematopoietic stem cell transplant in patients with hemato- logic neoplasms: a diagnostic dilemma for clinical cytogeneticists. Mol Cytogenet. 2016;9:62-68.
28. McGowan-Jordan J, Simons A, Schmid M: ISCN: An International System for Human Cytogenomic Nomenclature (2016). Basel, Switzerland: Karger, 2016.
29. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
30. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a compet- ing risk. Am Stat Assoc. 1999;94(446): 496- 509.
31. Gray RJ. A class of K-sample tests for com- paring the cumulative incidence of a com- peting risk. Ann Stat. 1988;16(3):1141-1154.
32. Ouyang J, Goswami M, Peng J, et al. Comparison of multiparameter flow cytom-
34. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472-1478.
35. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
36. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regula- tors and persist in remission. Proc Natl Acad Sci U S A. 2014;111(7):2548-2553.
37. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytoge- netically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14):2348-2355.
38. Getta BM, Devlin SM, Levine RL, et al. Multicolor flow cytometry and multigene next-generation sequencing are comple- mentary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation. Biol Blood Marrow Transplant. 2017;23(7):1064-1071.
39. Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189-1199.
haematologica | 2019; 104(2)
311